Assessment of dementia diagnosis using 3D facial mapping technology

Not Applicable

• Conditions: Alzheimer’s disease (AD), vascular dementia (VD), dementia with Lewy body (DLB), Parkinson’s disease dementia (PDD), frontal-temporal dementia (bvFTD); Nervous System Diseases; Alzheimer disease, vascular dementia, other specified degenerative diseases of nervous system, Parkinson disease

• Registration Number: ISRCTN11241743
• Lead Sponsor: Strong Room Technology Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-14
• Last Update Posted: 3 October 2023
• Study Completion: 2024-10-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

1. A diagnosis of dementia under the DSM-5 Criteria for Dementia for the dementia cohort using:
1.1. Medical history
1.2. Neuroimaging
1.3. Neuropsychological assessment
2. At least 8 years of education
3. Normal cognition under standardised testing for the age-matched healthy controls

Exclusion Criteria

1. Any significant facial deterioration through another disease or aetiology that could influence facial mapping or imaging
2. Patient diagnosed with Mild-Cognitive Impairment (MCI)
3. Patients diagnosed with mild memory impairment
4. Patients diagnosed with psychiatric conditions such as schizophrenia (due to presence of cataracts, lens opacities or corneal pigmentation) Smith et al., 1997 aggravated by poor performance on visual tasks (Hess et al., 1997 and Silverstein et al., 2000; 2009, 2012)
5. Patient diagnosed with neurological lesions such as cerebellar lesions as seen in Huntington’s, Wilson’s and Whipple Disease – can produce similar ocular hypometric, prolonged saccade latencies as seen in some types of dementia
6. Patients with underlying dermatological conditions such as dermatomyositis – as important facial landmarks and anatomy can be altered

Study & Design

• Study Type: Observational
• Study Design: Not specified